Organigram Q4 Sales Increase 76% to $3.2 Million

Results to August 31, 2018 showcase a Canadian leader in low-cost cultivation while growing high-quality indoor product

MONCTON, NB, Dec. 14, 2018 /PRNewswire/ – Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its 2018 fiscal year and fourth quarter results. The Company's fiscal year-end and fourth quarter encompasses operations up to and including August 31, 2018 and as a result, does not include adult-use recreational cannabis revenue.

"The importance of 2018 can not be overstated for Organigram as well as the industry," said Greg Engel, the Company's Chief Executive Officer. "We are incredibly proud of our ability to meet the challenges of scaling our business in preparation for the adult recreational use market. We are pleased with our progress to date and believe that we have performed well in a highly competitive space while always maintaining a sustainable cost structure. Ultimately, it is our view that our Moncton Campus will be seen as a crown jewel in the industry as it is able to produce consistent, high-quality indoor grown product at scale to support our brands with the lowest dried flower cultivation costs reported to date in Canada."

Select Highlights for Fiscal 2018

The Company is proud to report record net sales of $12.4 million for the 2018 fiscal year (up 131% from $5.4 million in 2017).

Gross margin increased to $52.5 million in 2018 from $(3.3) million in 2017. Excluding fair value adjustments on biological assets those figures would be $6.5 million and $(1.9) million, respectively.

Registered medical patients increased to 15,730 in 2018 from 7,404 in 2017 or 112%.

Reported net income of $20.5 million in 2018 up from $(10.9) million in 2017.

Outlook

Fiscal 2019 sales will be dominated by adult recreational use revenue and the Company estimates that Q1, 2019 sales will exceed that of the full year for fiscal 2018, despite only a portion of Q1, 2019 including adult recreational use market sales. Further, the Company expects that Q2, 2019 sales will exceed Q1, 2019 sales based on purchase orders received to date.

The Company reported biological assets and inventories of $19.9 million and $45.0 million, respectively, as of August 31, 2018. The Company believes that these balance sheet categories are an important indicator of a licensed producer's ability to service its medical and adult recreational customer.

The Company continues to add resources to refine and streamline its packaging, excise stamp application and logistics processes to draw down its dried flower and oil inventories to meet ongoing demand.

Based on media coverage and physical presence in stores, the Company is confident that it currently has the leading market share position in the Maritime provinces of New Brunswick, Nova Scotia and Prince Edward Island with a strong presence in Alberta, Manitoba, Newfoundland and Ontario.

Operational Highlights (also includes events after year-end)

Sales and Marketing

The Company has signed adult-use recreational supply deals or listing agreements with customers in nine out of the ten Canadian provinces (Quebec is the exception) and has already shipped to all nine of those provinces. Quebec remains a target for 2019.

Organigram has received positive feedback from its jurisdictional partners on fill rates as it has been proactive in setting and managing expectations as a reflection of its focus on long-term relationship building. Further to this, the Company has hired a national sales force from Tier 1 organizations to detail and educate retail staff on its brands.

The Company has successfully launched its Edison Cannabis Company brand focused on the four pillars of quality, sophistication, creativity and innovation as well as the Edison Reserve line which features hand-manicured and craft-cured top flower. The Company has also launched the Trailblazer brand, as a celebration of the industry's history for value-focused consumers. The Company anticipates launching its ANKR Organics and Trailer Park Buds lines in calendar 2019.

In October 2018, the Company was one of few licensed producers to successfully enter the adult recreational use market with a full line of compliant products including dried and milled flower, cannabis oil and pre-rolls.

Cultivation and Other Operations

Completion of Phase 2 and Phase 3 expansions at the Moncton Campus bring the total available grow rooms to 52 (13 smaller grow rooms from Phase 1 and 39 larger rooms from Phases 2 and 3). When fully utilized, these grow-rooms have a targeted production capacity of 36,000 kg/yr of dried flower (or equivalent) production.

Significant improvements in cash and all-in "cost of cultivation" from beginning of the year to end of the year. "Cost of cultivation" is a non-IFRS measurement that the Company tracks to assess the cost of the raw material that is ultimately sold or before it is extracted. "Costs of cultivation" includes direct labour, direct materials, and allocated overhead related to cultivation as well as non-cash measures such as depreciation and stock option compensation related to the operations department. Readers should be cautioned that this figure excludes packaging, shipping and SG&A and is not necessarily comparable between licensed producers. For internal purposes, the Company estimates a blended packaging estimate of $0.46 per dried flower gram equivalent and a blended shipping estimate of $0.19 per dried flower gram equivalent. These figures are estimates only.

"Cost of cultivation" is tracked as follows throughout the year:

Cash Cost

Non-Cash

Total

Q1-2018

$2.12

$0.53

$2.65

Q2-2018

$1.24

$0.24

$1.48

Q3-2018

$0.66

$0.14

$0.80

Q4-2018

$0.62

$0.21

$0.83

On October 24, 2018 the Company began utilizing power from a new 40 megawatt substation which provides the Company with a cleaner electrical supply, improves the Company's electrical consumption efficiency and lowers the Company's maintenance cost on equipment.

Phase 4 construction at the Moncton Campus began in July 2018. Phase 4 itself will be completed in stages: 4A, 4B and 4C. Phase 4A is expected to come online in April 2019 with 31 grow rooms, 4B in August 2019 with 32 grow rooms and 4C in October 2019 with 29 grow rooms bringing the Company's target production capacity to 62,000 kg/yr, 89,000 kg/yr and 113,000 kg/yr respectively.

Other Milestones and Strategic Initiatives

First International Medical Shipments – on July 6, 2018 and on September 24, 2018 the Company fulfilled its first shipments of dried flower and cannabis oil respectively to an Australian medical cannabis enterprise.

Investment in Hyasynth – on September 13, 2018 the Company entered into a strategic investment in convertible secured debentures of Hyasynth Biologicals Inc., a biotech company based in Montreal and leader in the field of cannabinoid science and biosynthesis. The initial investment of $5 million can increase up to $10 million upon achievement by Hyasynth of certain funding milestones. In addition to the investment, pursuant to an offtake agreement, Organigram has the right to purchase 25% of Hyasynth's cannabinoid production at a discount. Hyasynth's patent?pending enzymes, genetically engineered yeast strains and processes make it possible to produce phytocannabinoids and phytocannabinoid analogues through biosynthesis. To date, Hyasynth has already used its proprietary enzymes and yeast strains to produce CBG, CBD and THC and is currently in the process of scaling up to commercial production for cannabinoids to be used in novel and specialized products, including vaporizable cannabis products and cannabis?infused beverages, as well as pharmaceutical ingredients for a fraction of the cost of traditional plant?based production. Hyasynth will continue to develop a comprehensive platform of cannabinoids beyond THC, CBD and CBG for both medical and adult recreational use.

Investment in Eviana – on October 2, 2018 the Company completed a $5 million investment into Eviana Health Corporation, a CSE listed company with hemp operations in Serbia. Organigram entered into an offtake agreement with Eviana for up to 25% of the CBD production of Eviana for a period of five years at 95% of the wholesale price. Eviana holds certain assets in Serbia relating to the cultivation of industrial hemp plant including but not limited to: 310 metric tonnes of harvested hemp from 2017 to 2018; a 40,000 sq ft processing facility in Mladenovo, Serbia (near Novi Sad); and a 22,000 sq ft. pharma-grade leased facility in Belgrade which houses ethanol and CO2 extraction equipment.

Investment in Alpha-Cannabis Germany – on October 17, 2018 the Company announced a definitive agreement whereby the Company makes a 1.625 million Euro (approximately $2.44 million CAD) investment in Alpha-Cannabis Germany paid in cash with another 875,000 Euros (approximately $1.35 million CAD) payable on the achievement of certain milestones. As part of the investment and effective upon the closing of the investment, the Company's wholly?owned subsidiary, Organigram Inc. will enter into two supply agreements with ACG: one for the supply of cannabidiol isolate from ACG to Organigram Inc., and the other for the supply of dried cannabis flower from Organigram Inc. to ACG. In addition, ACG and Organigram Inc. anticipate entering into an agreement pursuant to which the companies will jointly evaluate and bid on certain licenses to supply medical cannabis to the German market.

Financial Highlights

The following results do not include any of the sales to the adult recreational use market which began in September to fill supply pipelines for adult recreational use launch on October 17, 2018. Those sales will be reflected in the first quarter of fiscal 2019 which includes the three-months ended November 30, 2018.

Summary of Financial Results

(in $000 except for per share amounts)

Q4-2018

Q4-2017

Inc.

(Decr.)

Fiscal

2018

Fiscal

2017

Inc.

(Decr.)

Sales

3,205

1,822

76%

11,936

7,417

61%

Sales recovery (returns)

8

–

n/m

493

(2,028)

n/m

Net sales

3,213

1,822

76%

12,429

5,389

131%

Cost of sales (incl. indirect production)

1,356

1,413

-4%

5,948

7,317

-19%

Gross margin (excluding FV adjustment)

1,857

409

354%

6,481

(1,928)

n/m

FV adjust on bio assets and inventories

30,846

265

11,540%

46,018

(1,369)

n/m

Gross margin

32,703

674

4752%

52,499

(3,297)

n/m

General and administrative

1,601

1,030

55%

5,552

3,276

69%

Sales and marketing

2,326

761

206%

6,303

2,825

123%

Share-based compensation (non-cash)

1,172

916

28%

4,228

1,703

148%

Net financing costs (income)

3,860

(76)

n/m

8,639

(288)

n/m

Income tax expense

5,653

–

n/m

5,653

–

n/m

Net income (loss) from continuing operations

18,091

(1,957)

n/m

22,124

(10,813)

n/m

Loss from discontinued operations

(74)

(76)

-3%

(1,611)

(76)

2020%

Net income (loss) and comprehensive income

18,017

(2,033)

n/m

20,513

(10,899)

n/m

Net income (loss) from continuing operations per common share, basic

$0.157

$(0.020)

n/m

$0.184

$(0.111)

n/m

Net income (loss) from continuing operations per common shares, diluted

$0.152

$(0.020)

n/m

$0.174

$(0.111)

n/m

Net income (loss) from discontinued operations per common share, basic

$(0.001)

$(0.001)

n/m

$(0.013)

$(0.001)

1200%

Net income (loss) from discontinued operations per common shares, diluted

$(0.001)

$(0.001)

n/m

$(0.013)

$(0.001)

1200%

Selected Balance Sheet Highlights and Financial Position

(in $000)

Aug-31-2018

Aug-31-2017

Inc.(Decr.)

Cash and short-term investments

130,064

33,957

283%

Biological assets

19,858

2,780

614%

Inventories

44,969

2,626

1,612%

Other current assets

8,323

5,304

57%

Property, plant and equipment

98,639

45,346

118%

Other non-current assets

714

2,795

-74%

Total assets

302,567

92,808

226%

Current liabilities

11,250

6,649

69%

Non-current liabilities

106,723

3,129

3,311%

Total liabilities

117,973

9,778

1,107%

Shareholders' equity

184,594

83,030

122%

Total Liabilities and Shareholders' Equity

302,567

92,808

226%

Capital Structure

Aug-31-2018

Aug-31-2017

(in $000)

Long-term debt

$ 2,877

$ 3,129

Convertible debentures carrying value

(with face value in parenthesis)

95,866

(110,329)

–

Deferred tax liability

7,980

–

Shareholders' equity

184,594

83,030

Total long-term debt and shareholders' equity

$ 291,317

$ 86,159

(in 000s)

Outstanding shares

125,208

103,595

Options

7,710

6,352

Warrants

8,087

4,329

Restricted share units

145

–

Convertible debentures (if converted at $5.42)

20,845

–

Fully-diluted shares

161,995

114,276

Prior to year-end August 31, 2018, approximately $2 million of face value of debentures were converted into common shares at a $5.42 conversion price. Subsequent to year-end, approximately $15 million more of face value of debentures were converted into common shares leaving approximately $98 million of the face value of debentures outstanding.

Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company's global footprint. In anticipation of the legal adult use recreational cannabis in Canada, Organigram has developed a portfolio of brands including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram's primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and theregulations under the Cannabis Act.

I want to learn more about…

CannabisLatest Stock Picks

I want to learn more about…

CannabisLatest Stock Picks

The Green Fund is Asia Pacific's preeminent media house, positioned at the forefront of the global cannabis industry. Committed to driving the industry forward, we spotlight the sector from all angles, explore the companies and the players making headlines, and cover some of the biggest cannabis companies in the world.

Any financial product advice provided in this website is general in nature. Content on this website does not take into account the objectives, financial situation or needs of any person, or purport to be comprehensive or constitute investment advice and should not be relied upon as such. You should consult a professional adviser to help you form your own opinion of the information and on whether the information is suitable for your individual objectives and needs as an investor. Where necessary, you should obtain a Product Disclosure Statement relating to the product and consider it before making any decision about whether to acquire the product. Read More

The content of this website does not constitute an offer by any representative of The Green Fund to buy or sell any financial products or services. Accordingly, reliance should not be placed solely on the content of this website, including any reports or recommendations, as the basis for making an investment, financial or other decision.

Recipients should not act on any report or recommendation issued by The Green Fund without first consulting a professional advisor in order to ascertain whether the recommendation (if any) is appropriate, having regard to their investment objectives, financial situation and particular needs. Any opinions expressed are subject to change without notice and may not be updated by The Green Fund.

The Green Fund believes the information contained in this website is correct. All information, opinions, conclusions, estimates, reports or recommendations provided are included with due care to its accuracy; however, no representation or warranty is made as to their accuracy, completeness, or reliability.

The Green Fund disclaims all liability and responsibility for any direct or indirect loss, or damage, which may be incurred by any recipient through any information, omission, error, or inaccuracy contained within any report or recommendation.

The views expressed in any report or recommendation are those of the analyst writing the report and no part of the compensation received by the analyst is directly related to the inclusion of specific recommendations or opinions.

The Green Fund and / or its associates may hold interests in the entities mentioned in any posted report or recommendation.

The Green Fund, or its representatives, may have relationships with the companies mentioned in posted reports - for example, acting as corporate advisor, dealer, broker, or holder of principal positions. The Green Fund and / or its representatives may also transact in those securities mentioned in the report, in a manner not consistent with recommendations made in the report.

Any recommendations or opinions stated in a report are done so based on assumptions made by The Green Fund.

The information provided in any report and on which it is based may include projections and / or estimates which constitute forward-looking statements. These expressed beliefs of future performance, events, results, or returns may not eventuate and as such no guarantee of these future scenarios is given or implied by The Green Fund. Any forward looking statements are subject to uncertainties and risks that may mean those forecasts made by The Green Fund are materially different to actual events. Show Less